See more : AGNC Investment Corp. (AGNCL) Income Statement Analysis – Financial Results
Complete financial analysis of AgeX Therapeutics, Inc. (AGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AgeX Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Overstock.com, Inc. (OSTK) Income Statement Analysis – Financial Results
- Target Capital Inc. (TRGCF) Income Statement Analysis – Financial Results
- Ryan Specialty Holdings, Inc. (RYAN) Income Statement Analysis – Financial Results
- Tesgas S.A. (TSG.WA) Income Statement Analysis – Financial Results
- Streamify AB (STREAM.ST) Income Statement Analysis – Financial Results
AgeX Therapeutics, Inc. (AGE)
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 34.00K | 144.00K | 1.87M | 1.73M | 1.40M | 1.40M |
| Cost of Revenue | 171.00K | 13.00K | 19.00K | 158.00K | 244.00K | 364.00K | 168.00K |
| Gross Profit | -29.00K | 21.00K | 125.00K | 1.71M | 1.48M | 1.03M | 1.24M |
| Gross Profit Ratio | -20.42% | 61.76% | 86.81% | 91.54% | 85.88% | 73.93% | 88.03% |
| Research & Development | 603.00K | 1.03M | 1.46M | 4.98M | 5.90M | 6.63M | 5.78M |
| General & Administrative | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Other Expenses | 11.00K | 13.00K | 448.00K | 44.00K | 294.00K | 183.00K | 38.00K |
| Operating Expenses | 9.93M | 7.00M | 8.16M | 12.38M | 14.04M | 12.28M | 9.65M |
| Cost & Expenses | 10.10M | 7.01M | 8.18M | 12.54M | 14.29M | 12.64M | 9.82M |
| Interest Income | 0.00 | 3.34M | 1.10M | 404.00K | 29.00K | 0.00 | 0.00 |
| Interest Expense | 4.90M | 3.34M | 1.10M | 0.00 | 0.00 | 116.00K | 0.00 |
| Depreciation & Amortization | 131.00K | 145.00K | 579.00K | 1.68M | 951.00K | 535.00K | 682.00K |
| EBITDA | -9.83M | -6.98M | -7.93M | -9.15M | -11.61M | -10.71M | -9.49M |
| EBITDA Ratio | -6,921.83% | -20,088.24% | -5,180.56% | -481.21% | -671.76% | -767.19% | -675.85% |
| Operating Income | -9.96M | -6.98M | -8.04M | -10.67M | -12.56M | -11.25M | -6.66M |
| Operating Income Ratio | -7,014.08% | -20,514.71% | -5,582.64% | -571.25% | -726.79% | -805.52% | -474.57% |
| Total Other Income/Expenses | -4.85M | -3.55M | -649.00K | 272.00K | 323.00K | 3.51M | 1.78M |
| Income Before Tax | -14.81M | -10.52M | -8.58M | -11.13M | -12.24M | -7.73M | -6.64M |
| Income Before Tax Ratio | -10,430.28% | -30,947.06% | -5,959.72% | -595.61% | -708.10% | -553.80% | -472.72% |
| Income Tax Expense | -8.00K | 152.00K | 1.64M | -150.00K | 148.00K | 3.51M | -1.80M |
| Net Income | -14.80M | -10.67M | -10.22M | -10.98M | -12.38M | -7.50M | -6.58M |
| Net Income Ratio | -10,424.65% | -31,394.12% | -7,097.22% | -587.58% | -716.67% | -537.39% | -468.66% |
| EPS | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EPS Diluted | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| Weighted Avg Shares Out | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
5 Financial Tasks To Be Completed By 31 July
Income Tax Return Filing: Filing ITR? Make sure to check your latest Form 26AS first — here’s why
An ROR must file income tax return inIndia if he or she holds any foreign asset
Waiting for your tax refund? Know the reasons for delay and check the status
Filing income tax return? Don’t make these mistakes to ensure you don’t get a tax notice
Going to file your Income Tax Return? Know which ITR Form to use
7 Instances Where You Can Receive Income Tax Notice
Beware! These seven ITR filing mistakes can lead to an income tax notice
The big-ticket transactions that can bring you under the radar of the I-T dept
New Form 26AS for Income Tax Return (ITR) filing: What has changed, how is it useful?
Source: https://incomestatements.info
Category: Stock Reports